We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Earnings season marches on, and we're here to spotlight the companies set to unveil their financial results in the next trading day. As Friday approaches, investors are eagerly anticipating reports ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tim Anderson from Bank of ...

AbbVie Inc. closed 14.67% below its 52-week high of $207.32, which the company achieved on October 31st.

Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for AbbVie in a report released on Tuesday, ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $170.67 which represents a slight increase of $1.47 or 0.87% from the prior close of $169.2. The stock opened at $170.46 and touched a ...

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ...